Immuno-Inclusivity in Opera

Part 4: Toolkit and Resources

Vaccination

Part 4: Toolkit and Resources: contents
  1. Part 4: Toolkit and Resources
  2. 4.1 Checklists
  3. 4.2 Top tools and how to use them
  4. Hazard assessments
  5. Going digital and remote
  6. Cleaning the air
  7. Natural ventilation
  8. Mechanical ventilation and filtration
  9. Portable air purifiers
  10. UV air disinfection
  11. Air quality monitoring
  12. Masks and respirators
  13. Personnel placement and scheduling
  14. Vaccination
  15. Testing and screening
  16. Cleaning, sanitizing, and disinfecting surfaces
  17. Reducing allergies and environmental hazards
  18. Communication and training
  19. Accommodations and conflicting access needs

Vaccines have saved over 150 million lives in the past 50 years, and are a vital tool in a layered health & safety strategy.Footnote 193 Depending on the illness, vaccines may strongly reduce infection and transmission (e.g., for measles),Footnote 194 or they may reduce risks of hospitalization and death even when they do not fully prevent transmission or long-term health impacts (e.g., for COVID-19).Footnote 195 Higher community vaccination rates can decrease risk of outbreaks, and in some circumstances, lead to regional elimination of an illness.Footnote 196 There is consistent evidence that some vaccines can provide added benefits (e.g., reducing risks of heart attacks, strokes, dementia).Footnote 197

While vaccines are safe and effective for the vast majority of people, some people cannot get all types of vaccines.Footnote 198 Immunocompromised people often receive weaker protection from vaccines,Footnote 199 and protection can wane over time or with new illness variants.Footnote 200 Some infectious illnesses like measles can cause immune damage that may erase previous immunity, known as “immune amnesia.”Footnote 201

Even when vaccinated, it remains important to use layered health & safety measures—especially as some contagious illnesses do not yet have vaccines.Footnote 202 By encouraging consistent, up-to-date vaccination among those who are able, production teams can create a healthier environment for everyone.

Strategies to support vaccination:

  • Education and resources: Provide information about vaccination (communicable disease plans, health & safety manuals, safety bulletins)
  • Workplace initiatives: Consider voluntary “pledge” campaigns, peer presenters, and community representativesFootnote 203
  • Staff support: Share information about vaccine clinics; offer time off to be vaccinated; and offer on-site vaccination if possible
  • Policy: Follow public health and travel vaccine requirements and recommendations; consider developing workplace vaccine policies, in proportion to the hazard and aligned with human rights obligationsFootnote 204
Footnotes (12)
  1. Andrew J Shattock et al., “Contribution of Vaccination to Improved Survival and Health: Modelling 50 Years of the Expanded Programme on Immunization,” The Lancet 403, no. 10441 (2024): 2307–16, https://doi.org/10.1016/S0140-6736(24)00850-X. Back to text
  2. Carlo Di Pietrantonj et al., “Vaccines for Measles, Mumps, Rubella, and Varicella in Children,” Cochrane Database of Systematic Reviews 11 (2021), https://doi.org/10.1002/14651858.CD004407.pub5. Back to text
  3. Ryan E. Wiegand et al., “Interim Estimated Effectiveness of 2025–2026 COVID-19 Vaccines in Adults Using a Test-Negative Design,” JAMA Network Open 9, no. 6 (2026): e2625152, https://doi.org/10.1001/jamanetworkopen.2026.25152; Guiling Zhou et al., “Effectiveness of COVID-19 Vaccines Against SARS-CoV-2 Infection and Severe Outcomes in Adults: a Systematic Review and Meta-Analysis of European Studies Published Up to 22 January 2024,” European Respiratory Review 34, no. 175 (2025): 240222, https://doi.org/10.1183/16000617.0222-2024; Anika Singanayagam et al., “Community Transmission and Viral Load Kinetics of the SARS-CoV-2 Delta (B.1.617.2) Variant in Vaccinated and Unvaccinated Individuals in the UK: a Prospective, Longitudinal, Cohort Study,” The Lancet Infectious Diseases 22, no. 2 (2021): 183–95, https://doi.org/10.1016/S1473-3099(21)00648-4; Ziyad Al-Aly et al., “Long COVID After Breakthrough SARS-CoV-2 Infection,” Nature Medicine 28 (2022): 1461–67, https://doi.org/10.1038/s41591-022-01840-0; Rhiannon Green et al., “A Systematic Review and Meta-Analysis of the Impact of Vaccination on Prevention of Long COVID,” Nature Communications 16 (2025): 10326, https://doi.org/10.1038/s41467-025-65302-0. Back to text
  4. Canada, “Vaccines in Canada: Why Meeting our Routine Vaccination Goals Matters,” The Science of Health, Government of Canada, last modified February 1, 2026, https://science.gc.ca/site/science/en/blogs/science-health/vaccines-canada-why-meeting-our-routine-vaccination-goals-matters; Public Health Agency of Canada, “Statement from the Public Health Agency of Canada on Canada’s Measles Elimination Status,” news release, November 10, 2025, https://www.canada.ca/en/public-health/news/2025/11/statement-from-the-public-health-agency-of-canada-on-canadas-measles-elimination-status.html; World Health Organization and United States Centers for Disease Control and Prevention, “Nearly 40 Million Children are Dangerously Susceptible to Growing Measles Threat,” news release, November 23, 2022, https://www.who.int/news/item/23-11-2022-nearly-40-million-children-are-dangerously-susceptible-to-growing-measles-threat; World Health Organization, “Measles Deaths Down 88% Since 2000, but Cases Surge,” news release, November 28, 2025, https://www.who.int/news/item/28-11-2025-measles-deaths-down-88--since-2000--but-cases-surge; World Health Organization, “History of Polio Vaccine,” World Health Organization, accessed July 12, 2026, https://www.who.int/news-room/spotlight/history-of-vaccination/history-of-polio-vaccination. Back to text
  5. Stefania Maggi et al., “Association Between Vaccinations and Risk of Dementia: a Systematic Review and Meta-Analysis,” Age and Ageing 54, no. 11 (2025): afaf331, https://doi.org/10.1093/ageing/afaf331; M. Naghavi et al., “Association of Influenza Vaccination and Reduced Risk of Recurrent Myocardial Infarction,” Circulation 102, no. 25 (2000): 3039–45, https://doi.org/10.1161/01.cir.102.25.3039; Philippa Lavallée et al., “Association Between Influenza Vaccination and Reduced Risk of Brain Infarction,” Stroke 33, no. 2 (2002): 513–18, https://doi.org/10.1161/hs0202.102328; Markus Eyting et al., “A Natural Experiment on the Effect of Herpes Zoster Vaccination on Dementia,” Nature 641 (2025): 438–46, https://doi.org/10.1038/s41586-025-08800-x; European Society of Cardiology, “New Systematic Review and Meta-Analysis Shows an Association Between Shingles Vaccination and Lower Risk of Heart Attack and Stroke,” news release, August 28, 2025, https://www.escardio.org/news/press/press-releases/New-systematic-review-and-meta-analysis-shows-an-association-between-shingles-vaccination-and-lower-risk-of-heart-attack-and-stroke. Back to text
  6. Agency for Healthcare Research and Quality, Safety of Vaccines Used for Routine Immunization in the United States: An Update, Comparative Effectiveness Review Number 244 (Agency for Healthcare Research and Quality, 2021), 155, https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-244-safety-vaccines.pdf; “Vaccine Safety,” Immunize Canada, last modified March 5, 2026, https://www.immunize.ca/vaccine-safety; World Health Organization, “Vaccines and Immunization: Vaccine Safety,” World Health Organization, September 23, 2025, https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-vaccine-safety; Institute of Medicine, The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies (The National Academies Press, 2013), 135, https://doi.org/10.17226/13563; Public Health Agency of Canada, “Contraindications and Precautions: Canadian Immunization Guide,” Canadian Immunization Guide, Public Health Agency of Canada, last modified April 9, 2026, https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-2-vaccine-safety/page-3-contraindications-precautions-concerns.html. Back to text
  7. Michael G. Ison, “Vaccines for Use in Special Populations: Immunocompromised Hosts,” The Journal of Infectious Diseases 231, no. 3 (2025): 552–55, https://doi.org/10.1093/infdis/jiae508; Kay Choong See, “Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews,” Vaccines (Basel) 10, no. 5 (2022): 800, https://doi.org/10.3390/vaccines10050800; Peter J. Embi et al., “Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations among Immunocompromised Adults — Nine States, January–September 2021,” MMWR Morbidity and Mortality Weekly Report 70 (2021): 1553–59, http://dx.doi.org/10.15585/mmwr.mm7044e3; Turtle et al., “Outcome of COVID-19,” 16; Guangtong Deng et al., “Risk and Outcomes of Breakthrough COVID-19 Infections in Vaccinated Immunocompromised Patients: A Meta-Analysis,” MedComm 4, no. 3 (2023): e307, https://doi.org/10.1002/mco2.307. Back to text
  8. Francesco Menegale et al., “Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity: A Systematic Review and Meta-Analysis,” JAMA Network Open 6, no. 5 (2023): e2310650, https://doi.org/10.1001/jamanetworkopen.2023.10650; “SARS-CoV-2 Vaccine Breakthrough Infections (VBI) by Omicron Variant (B.1.1.529) and Consequences in Structural and Functional Impact,” Cellular Signalling 109 (2023): 110798, https://doi.org/10.1016/j.cellsig.2023.110798; Velislava N. Petrova and Colin A. Russell, “The Evolution of Seasonal Influenza Viruses,” Nature Reviews Microbiology 16 (2018), 47–60; Public Health Agency of Canada, “COVID-19 Vaccines,” Canadian Immunization Guide, Public Health Agency of Canada, last modified June 9, 2026, https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a4; Dan-Yu Lin et al., “Durability of XBB.1.5 Vaccines Against Omicron Subvariants,” New England Journal of Medicine 390, no. 22 (2024): 2124–27, https://doi.org/10.1056/NEJMc2402779; Stephanie Souchera, “With an Absent CDC and Mismatched ‘Subclade K’ Flu Strain, Experts Face Upcoming Season with Uncertainty,” Center for Infectious Disease Research and Policy, November 12, 2025, https://www.cidrap.umn.edu/influenza-vaccines/absent-cdc-and-mismatched-subclade-k-flu-strain-experts-face-upcoming-season. Back to text
  9. Shaw, “How Measles Causes Immune Amnesia.” Back to text
  10. Mateusz Hasso-Agopsowicz et al., “Identifying WHO Global Priority Endemic Pathogens for Vaccine Research and Development (R&D) Using Multi-Criteria Decision Analysis (MCDA): An Objective of the Immunization Agenda 2030,” eBioMedicine 110 (2024): 105424, https://doi.org/10.1016/j.ebiom.2024.105424. Back to text
  11. Canada, “Addressing Vaccine Hesitancy in the Context of COVID-19: A Primer for Health Care Providers,” Government of Canada, last modified May 7, 2021, https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/vaccines/vaccine-hesitancy-primer.html; Lisa Menning and Jun Ryan Orbina, Helping People Get Vaccinated — Quick Tips for Community Representatives (World Health Organization, 2026), https://www.technet-21.org/en/resources/tool/quick-tips-for-community-representatives-2. Back to text
  12. British Columbia’s Office of the Human Rights Commissioner, A Human Rights Approach to Proof of Vaccination During the COVID-19 Pandemic (British Columbia’s Office of the Human Rights Commissioner, 2021), https://bchumanrights.ca/wp-content/uploads/COVID-19-vaccine-guidance-Oct.-2021-update.pdf. Back to text
Part 4: Toolkit and Resources: contents
  1. Part 4: Toolkit and Resources
  2. 4.1 Checklists
  3. 4.2 Top tools and how to use them
  4. Hazard assessments
  5. Going digital and remote
  6. Cleaning the air
  7. Natural ventilation
  8. Mechanical ventilation and filtration
  9. Portable air purifiers
  10. UV air disinfection
  11. Air quality monitoring
  12. Masks and respirators
  13. Personnel placement and scheduling
  14. Vaccination
  15. Testing and screening
  16. Cleaning, sanitizing, and disinfecting surfaces
  17. Reducing allergies and environmental hazards
  18. Communication and training
  19. Accommodations and conflicting access needs